Genialis
Founded Year
2015Stage
Series A | AliveTotal Raised
$15.76MLast Raised
$13M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-5 points in the past 30 days
About Genialis
Genialis is an RNA biomarker company focused on advancing translational research and cancer drug development within the healthcare sector. The company specializes in discovering RNA biomarkers using machine learning, which aids in positioning oncology drugs, stratifying clinical trials, and developing diagnostic tests to predict patient responses and guide treatment decisions. Genialis collaborates with pharmaceutical and diagnostics companies to deliver precision medicine solutions that aim to improve clinical outcomes. It was founded in 2015 and is based in Boston, Massachusetts.
Loading...
ESPs containing Genialis
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The life science cloud research and development (R&D) platforms market refers to the use of cloud-based technologies in R&D activities in the life sciences field. The market is driven by the need to improve efficiency and collaboration among researchers, as well as the increasing availability of big data and the need for advanced analytics. By leveraging the power of cloud computing, life science …
Genialis named as Challenger among 14 other companies, including Schrodinger, Rescale, and TetraScience.
Loading...
Expert Collections containing Genialis
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Genialis is included in 1 Expert Collection, including Digital Health.
Digital Health
11,072 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Genialis Patents
Genialis has filed 10 patents.
The 3 most popular patent topics include:
- cooling technology
- cryogenics
- fluid dynamics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/18/2016 | 1/23/2024 | Cakes, Polysaccharides, Food additives, Pastries, Sugar substitutes | Grant |
Application Date | 10/18/2016 |
|---|---|
Grant Date | 1/23/2024 |
Title | |
Related Topics | Cakes, Polysaccharides, Food additives, Pastries, Sugar substitutes |
Status | Grant |
Latest Genialis News
Sep 4, 2024
News Provided By Share This Article Company recognized for advances in RNA- and AI-based diagnostic algorithms; will present new advancements at key industry conferences in September BOSTON, MA, UNITED STATES, September 4, 2024 / EINPresswire.com / -- Genialis, the RNA biomarker company, announced today, ahead of the 14th World Clinical Biomarkers & Companion Diagnostics Summit, that it has been named a finalist for the Biotech Week Boston (BWB) Awards in the category of Biotech Innovation. This recognition highlights Genialis’ commitment to advancing precision medicine through its innovative biology-first approach to machine learning. The Biotech Innovation award honors companies and organizations that have conceived new or advanced biopharmaceutical products, manufacturing processes, or groundbreaking technologies yielding significant results. Genialis was selected for its application of machine learning to develop RNA biomarkers that have demonstrated significant improvements in predicting patient responses to targeted cancer therapies. A prime example is Genialis™ krasID , a patient classifier introduced at the AACR 2024 Annual Meeting, which stratifies clinical benefit of KRAS inhibition and identifies patients most likely to respond to KRASi with over 84% precision . “We are honored to be recognized by Biotech Week Boston for our efforts to reimagine diagnostic development,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “This nomination highlights our commitment to enable the most informed treatment decisions and improve patient outcomes. We look forward to sharing our latest and greatest at several conferences this September.” Genialis will be participating at various industry events in Boston this month to present new data and additional validation studies that further demonstrate the clinical utility of its diagnostic algorithms. Industry leaders, researchers, and potential collaborators are invited to connect with the team at the 14th World Clinical Biomarkers & Companion Diagnostics Summit (Sept 4-6), PanCAN Scientific Summit 2024 (Sept 14-15), AACR Special Conference: Advances in Pancreatic Cancer Research (Sept 15-18), and the 6th Annual RAS-Targeted Drug Development Summit (Sept 24-26). To schedule a meeting or learn more about Genialis’ biomarker programs, please visit https://www.genialis.com/rna-biomarkers or email biomarkers@genialis.com. About Genialis Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. For more information, please visit www.genialis.com . Andrea Vuturo
Genialis Frequently Asked Questions (FAQ)
When was Genialis founded?
Genialis was founded in 2015.
Where is Genialis's headquarters?
Genialis's headquarters is located at 177 Huntington Avenue, Boston.
What is Genialis's latest funding round?
Genialis's latest funding round is Series A.
How much did Genialis raise?
Genialis raised a total of $15.76M.
Who are the investors of Genialis?
Investors of Genialis include Redalpine Venture Partners, First Star Ventures, Pikas, Hikma Ventures, Debiopharm Investment and 6 more.
Who are Genialis's competitors?
Competitors of Genialis include Envisagenics and 6 more.
Loading...
Compare Genialis to Competitors
Caris focuses on molecular science, specifically in the domain of cancer care. The company offers services such as molecular profiling, blood profiling, and tissue profiling, which provide comprehensive molecular information to help oncologists create personalized treatment plans for cancer patients. It primarily sells to the healthcare industry, particularly oncology. It was founded in 1996 and is based in Irving, Texas.
Rosa is a drug development advisory firm specializing in Quantitative Systems Pharmacology (QSP) and market modeling within the pharmaceutical industry. The company offers PhysioPD Research Platforms that translate complex biological mechanisms into interactive mathematical models to aid in therapeutic intervention analysis and clinical outcome predictions. Additionally, Rosa provides Market Modeling services to quantify product attributes that influence prescriber uptake and to assess a product's competitive market potential. It was founded in 2002 and is based in San Carlos, California.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Insilico Medicine operates as a clinical-stage biotechnology company operating in pharmaceutical research and development. It offers services such as novel target discovery, generation of molecular structures with desired properties, and clinical trial analysis. Its services primarily cater to the healthcare industry, with a particular emphasis on the discovery and development of innovative drugs for a range of conditions including cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI Foundation Models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
DarwinHealth is a precision-focused cancer medicine company operating in the healthcare sector. The company offers proprietary algorithms and methodologies to match individual cancer patients with optimal drug and drug combinations for successful treatment outcomes. Additionally, these methodologies are used to prioritize drugs and drug combinations for pharmaceutical companies, optimizing their developmental compound pipelines. It is based in New York, New York.
Loading...